Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $9.50.

A number of research analysts have recently commented on SANA shares. Weiss Ratings downgraded Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Sunday, June 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $12.00 price target on shares of Sana Biotechnology in a report on Friday, March 13th. Rodman & Renshaw assumed coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, HC Wainwright cut their price objective on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th.

Sana Biotechnology Trading Up 2.0%

Shares of NASDAQ:SANA opened at $3.56 on Thursday. Sana Biotechnology has a 52 week low of $2.61 and a 52 week high of $6.55. The company’s 50 day moving average is $3.20 and its two-hundred day moving average is $3.68. The company has a market cap of $990.71 million, a PE ratio of -3.83 and a beta of 2.13.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, equities research analysts expect that Sana Biotechnology will post -0.59 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SANA. Royal Bank of Canada lifted its position in Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock valued at $35,000 after acquiring an additional 5,338 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Sana Biotechnology during the third quarter worth about $36,000. Rockefeller Capital Management L.P. increased its position in shares of Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Sana Biotechnology during the third quarter worth about $39,000. Finally, LRI Investments LLC acquired a new stake in shares of Sana Biotechnology during the fourth quarter worth about $41,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.